Download PDF
Thromb Haemost 1963; 09(02): 368-386
DOI: 10.1055/s-0038-1654991
Originalarbeiten — Original Articles — Travaux Originaux
Schattauer GmbH

Studies on Thrombin Inactivation in Normal Plasma, Serum and Plasma Fractions, and its Relation to Heparin[*]

Birger Blombäck
1   Chemistry Department II (Head: E. Jorpes), Karolinska Institutet, and the Department of Thoracic Surgery (Head: C. Crafoord), Karolinska Sjukhuset, Stockholm, Sweden
,
Margareta Blombäck
1   Chemistry Department II (Head: E. Jorpes), Karolinska Institutet, and the Department of Thoracic Surgery (Head: C. Crafoord), Karolinska Sjukhuset, Stockholm, Sweden
,
Per Olsson
1   Chemistry Department II (Head: E. Jorpes), Karolinska Institutet, and the Department of Thoracic Surgery (Head: C. Crafoord), Karolinska Sjukhuset, Stockholm, Sweden
› Author Affiliations
Further Information

Publication History

Publication Date:
24 July 2018 (online)

    Permissions and Reprints

Summary

The antithrombin activity of plasma, serum and plasma fractions has been studied under different experimental conditions. Two different methods have been used for the assay of antithrombin activity.

Under the experimental conditions described the following antithrombin activities have been found to be of importance in the inactivation of thrombin:

1. Progressive inactivation in the absence of heparin can take place in plasma and to a less extent in defibrinated plasma and serum.

2. Inactivation of thrombin in presence of fibrinogen and heparin in low concentration (about 0.03 I.U./ml). This effect was abolished at high heparin levels.

3. Inactivation of thrombin by plasma, defibrinated plasma and serum at high concentrations of heparin (about 2—15 I.U./ml). This activity is tentatively named the heparin co-factor.

* This investigation was supported by grants from the Swedish Medical Research Council, Harald och Greta Jeanssons Stiftelse, Research Grants No — 4295 (R 1 and C 1) to Professor Erik Jorpes from the National Heart Institute, National Institutes of Health, U. S. Public Health Service and Knut and Alice Wallenbergs Stiftelse.


 

  • References

  • 1 Astrup T, Darling S. Antithrombin and heparin. Acta physiol, scand. 05: 13 1943;
    CrossrefPubMedGoogle Scholar
  • 2 Bergmann M, Fruton J. S, Pollok H. The specificity of trypsin. J. biol. Chem. 127: 643 1939;
    PubMedGoogle Scholar
  • 3 Blombäck B, Blombäck M. Purification of human and bovine fibrinogen, Arkiv f. Kemi. 10: 415 1956;
    PubMedGoogle Scholar
  • 4 Blombäck B. On the properties of fibrinogen and fibrin. Ark. Kemi. 12: 99 1958;
    PubMedGoogle Scholar
  • 5 Blombäck B. Studies on the action of thrombic enzymes on bovine fibrinogen as measured by N-terminal analysis. Ark. Kemi. 12: 321 1958;
    PubMedGoogle Scholar
  • 6 Blombäck B, Vestermark A. Isolation of fibrino-peptides by chromatography. Ark. Kemi. 12: 173 1958;
    PubMedGoogle Scholar
  • 7 Blombäck B, Yamashina I. On the N-terminal amino acids in fibrinogen and fibrin. Ark. Kemi. 12: 299 1958;
    PubMedGoogle Scholar
  • 8 Burstein M, Guinand A. Héparine et consommation de l’antithrombine. Arch. int. Pharmacodyn. 104: 435 1955;
    PubMedGoogle Scholar
  • 9 Cohn E. J, Strong L. E, Hughes Jr. W. L, Mulford D. J, Ashworth J. N, Melin M, Taylor H. L. Preparation and properties of serum and plasma proteine. J. Amer. chem. Soc. 68: 459 1946;
    CrossrefPubMedGoogle Scholar
  • 10 Douglas A. S, Biggs R. The consumption of some components involved in physiological blood coagulation. Glasg. med. J. 34: 329 1953;
    PubMedGoogle Scholar
  • 11 Engelberg H. Plasma heparin levels in normal man. Circulation 23: 578 1961;
    CrossrefPubMedGoogle Scholar
  • 12 Ferguson J. H. Modus operandi of commercial heparin. Proc. Soc. exp. Biol. (N. Y) 37: 23 1937;
    CrossrefPubMedGoogle Scholar
  • 13 Gasser H. S. The significance of prothrombin and of free and combined thrombin in blood-serum. Amer. J. Physiol. 42: 378 1917;
    PubMedGoogle Scholar
  • 14 Gerendas M. Experimentelle Bestimmung des Thrombininaktivierungsprozesses. Ann. Inst. Biol. Hung. 01. 169 (1949—1950).
    PubMedGoogle Scholar
  • 15 Gerendäs M. Die Thrombinaktivierung als Enzymprozeß. Thrombos. Diathes. haemorrh. (Stuttg) 04: 56 1960;
    PubMedGoogle Scholar
  • 16 Gerendas M, Palos A. L, Csefko I. Heparin effect and thrombin inactivation. Ann. Inst. Biol. Hung. 01. 191 (1949—1950).
    PubMedGoogle Scholar
  • 17 Howell W. H, Holt E. Two new factors in blood coagulation — heparin and pro-antithrombin. Amer. J. Physiol. 47: 328 1918;
    PubMedGoogle Scholar
  • 18 Jaques L. B, Mustard R. A. Some factors influencing the anticoagulant action of heparin. Biochem. J. 34: 153 1940;
    CrossrefPubMedGoogle Scholar
  • 19 Jorpes J. E. Heparin in the treatment of thrombosis. Oxford Univ. Press; 2nd ed. Oxford: 1946
    Google Scholar
  • 20 Klein P. D, Seegers W. H. The nature of plasma antithrombin activity. Blood 05: 742 1950;
    PubMedGoogle Scholar
  • 21 Koller F, Derouaux G. Cit. by Surgenor D. M. Blood cells and plasma proteins. Ed. J. L. Tullis Academic Press; New York (N. Y): 1953: 72.
  • 22 Landsberg M. Studien zur Lehre von der Blutgerinnung. Biochem. 50: 245 1913;
    PubMedGoogle Scholar
  • 23 Loeb J. Le cofacteur plasmatique de l’heparine et les rapports avec l’antithrombine. Arch. Sci. physiol. 10: 129 1956;
    PubMedGoogle Scholar
  • 24 Loeliger A, Hers J. F. Ph. Chronic antithrombinaemia (antithrombin V) with hemorrhagic diathesis in a case of rheumatoid arthritis with hypergammaglobulinaemia. Thrombos. Diathes. haemorrh. (Stuttg) 01: 499 1957;
    PubMedGoogle Scholar
  • 25 Lyttleton J. W. The antithrombin activity of human plasma. Biochem. J. 58: 8 1954;
    CrossrefPubMedGoogle Scholar
  • 26 Lyttleton J. W. The antithrombin activity of heparin. Biochem. J. 58: 15 1954;
    CrossrefPubMedGoogle Scholar
  • 27 Markwardt F, Walsmann P. Untersuchungen über den Mechanismus der Antithrombinwirkung des Heparins. Hoppe-Seylers Z. physiol. Chem. 317: 64 1959;
    PubMedGoogle Scholar
  • 28 Mellanby J. Heparin and blood coagulation. Proc. Roy. Soc. 116: 1 1934;
    CrossrefPubMedGoogle Scholar
  • 29 Mihalyi E. Observations on thrombin inactivation by human serum. J. gen. Physiol. 37. 139 (1953/54).
    PubMedGoogle Scholar
  • 30 Monkhouse F. C, France E. S, Seegers W. H. Studies on the antithrombin and heparin co-factor activities of a fraction adsorbed from plasma by aluminium hydroxide. Circulat. Res. 03: 397 1955;
    CrossrefPubMedGoogle Scholar
  • 31 Niewiarowski S, Kowalski E, Stachurska J. Un nouvel anticoagulant dérivé du fibrinogène. Rev. Hémat. 13: 320 1958;
    PubMedGoogle Scholar
  • 32 Nilsson I. M, Wenckert A. Demonstration of a heparin-like anticoagulant in normal blood. I. Human blood. Acta med. scand. (suppl). 150: 297 1954;
    PubMedGoogle Scholar
  • 33 Owen C. A, Bollman J. L. Serum and plasma antithrombin. Proc. Soc. exp. Biol. (N. Y). 67: 367 1948;
    CrossrefPubMedGoogle Scholar
  • 34 Quick A. J. The normal antithrombin of the blood and its relation to heparin. Amer. J. Physiol. 123: 712 1938;
    PubMedGoogle Scholar
  • 35 Schmitz A, Kühl L. Die Inaktivierung des Heparins in Blut. Hoppe-Seylers Z. physiol. Chem. 234: 212 1935;
    PubMedGoogle Scholar
  • 36 Seegers W. H, Warner E. D, Brinkhous K. M, Smith H. P. Heparin and the antithrombin activity of plasma. Science 96: 300 1942;
    CrossrefPubMedGoogle Scholar
  • 37 Seegers W. H, Nieft M, Loomis E. C. Note on the adsorption of thrombin and fibrin. Science 101: 520 1945;
    CrossrefPubMedGoogle Scholar
  • 38 Seegers W. H, Loomis E. C, Vandenbelt J. M. Preparation of prothrombin products: Isolation of prothrombin and its properties. Arch. Biochem. 06: 85 1945;
    PubMedGoogle Scholar
  • 39 Seegers W. H, Miller K. D, Andrews E. B, Murphy R. C. Fundamental interactions and the effect of storage, ether, adsorbants and blood clotting on plasma antithrombin activity. Amer. J. Physiol. 169: 700 1952;
    PubMedGoogle Scholar
  • 40 Seegers W. H, Johnson J. F, Fell C. An antithrombin reaction related to prothrombin activation. Amer. J. Physiol. 176: 97 1954;
    PubMedGoogle Scholar
  • 41 Seegers W. H, Yoshinari M, Landaburu R. H. Antithrombin as substrate for the enzyme thrombin. Thrombos. Diathes. haemorrh. (Stuttg) 04: 293 1960;
    PubMedGoogle Scholar
  • 42 Sherry S, Troll W. The action of thrombin on synthetic substrates. J. biol. Chem. 208: 95 1954;
    PubMedGoogle Scholar
  • 43 Shinowara G. Y, Buckley D. J. Isolation of antithrombin globulin from human blood plasma. Thrombos. Diathes. haemorrh. (Stuttg) 04: 17 1960;
    PubMedGoogle Scholar
  • 44 Waugh D. F, Fitzgerald M. A. Quantitative aspects of antithrombin and heparin in plasma. Amer. J. Physiol. 184: 627 1958;
    PubMedGoogle Scholar
  • 45 Wilander O. Studien über Heparin. Skand. Arch. Physiol. 81 Suppl. 15 1938;
    PubMedGoogle Scholar